Intellia Therapeutics (38I) Financial Statements
Intellia Therapeutics Financial Overview
Intellia Therapeutics's market cap is currently $1.44B. The company's EPS TTM is $-3.36; its P/E ratio is -3.71; Intellia Therapeutics is scheduled to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.66. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 67.67M | $ 57.88M | $ 36.27M | $ 52.12M | $ 33.05M |
| Gross Profit | $ 51.75M | $ 47.59M | $ 27.30M | $ 44.55M | $ 26.16M |
| Operating Income | $ -440.99M | $ -534.26M | $ -515.29M | $ -458.16M | $ -267.85M |
| EBITDA | $ -396.77M | $ -508.74M | $ -472.22M | $ -466.61M | $ -261.00M |
| Net Income | $ -412.69M | $ -519.02M | $ -481.19M | $ -474.19M | $ -267.89M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 449.88M | $ 601.51M | $ 912.22M | $ 1.19B | $ 748.69M |
| Total Assets | $ 842.13M | $ 1.19B | $ 1.30B | $ 1.52B | $ 1.29B |
| Total Debt | $ 93.33M | $ 210.20M | $ 115.35M | $ 130.70M | $ 74.02M |
| Net Debt | $ -62.13M | $ 21.02M | $ -111.40M | $ -392.80M | $ -49.38M |
| Total Liabilities | $ 170.73M | $ 319.06M | $ 250.81M | $ 284.53M | $ 254.22M |
| Stockholders' Equity | $ 671.39M | $ 871.96M | $ 1.05B | $ 1.24B | $ 1.04B |
| Cash Flow | |||||
| Free Cash Flow | $ -354.66M | $ -354.66M | $ -408.07M | $ -391.68M | $ -237.79M |
| Operating Cash Flow | $ -348.88M | $ -348.88M | $ -394.09M | $ -333.29M | $ -225.03M |
| Investing Cash Flow | $ 125.57M | $ 125.57M | $ -31.35M | $ 160.31M | $ -550.78M |
| Financing Cash Flow | $ 185.75M | $ 185.75M | $ 130.32M | $ 582.96M | $ 736.69M |
Currency in USD